FDA | No useful monoclonal antibody treatments left against new COVID-19 variants.
7 Dec, 2022 | 14:31h | UTCFDA: No Useful Monoclonal Antibody Treatments Left Against New COVID-19 Variants – HealthDay
Related: Study shows Omicron sublineage BQ.1.1 is resistant to all monoclonal antibodies.